Levicept Unveils Groundbreaking Phase 2 Data for LEVI-04
Levicept has unveiled compelling new data from its Phase 2 clinical trial of LEVI-04, a first-in-class biologic designed to provide non-addictive pain relief, at the European Congress of Rheumatology (EULAR) 2025.
The findings, presented in an oral session on June 14 by Professor Philip Conaghan, Director of the NIHR Leeds Biomedical Research Centre, signal a potential paradigm shift in the treatment of knee osteoarthritis.
A Unique Mechanism with Tangible Results
LEVI-04 is a proprietary p75 neurotrophin receptor fusion protein that works by inhibiting NT-3 activity, helping to modulate excessive neurotrophin levels – a known contributor to chronic pain in osteoarthritis.
This innovative mechanism sets LEVI-04 apart from conventional treatments, especially in a space where addiction risk and tolerability remain major concerns with current options.
The randomised, double-blind Phase 2 trial, involving 518 participants, had previously demonstrated significant analgesia across all dosage levels. However, Levicept’s latest analysis presented at EULAR offers deeper insight.
Not only did patients experience rapid pain relief within just three days, but they also reported greater-than-expected improvement in physical function – an encouraging signal that LEVI-04 may positively impact mobility and quality of life, not merely mask discomfort.
Beyond Pain: Elevating Patient Functionality
The improvements in patient-reported outcomes were described by Professor Conaghan as clinically meaningful, highlighting that functional gains went well beyond what could be explained by pain relief alone.
Such a result is particularly significant for a condition like osteoarthritis, where diminished mobility often compounds the burden of pain.
To reinforce these outcomes, Levicept also presented results from a novel evoked pain model, which further demonstrated LEVI-04’s efficacy over placebo. These findings provide a strong scientific basis for optimism, especially given the historical challenge of balancing efficacy with safety in long-term osteoarthritis management.
Industry Attention and the Road Ahead
Levicept’s CEO noted the increasing global interest the company continues to receive at international medical congresses, positioning LEVI-04 as a standout candidate in the pipeline of future osteoarthritis therapies.
With an emphasis on advancing development strategies, the company remains focused on moving swiftly toward the next clinical phases, ensuring that patients most in need of effective, safe, and non-addictive options are not left waiting.
A New Horizon for Osteoarthritis Treatment
With millions affected by knee osteoarthritis worldwide, the emergence of LEVI-04 offers a much-needed dose of hope. Its ability to rapidly relieve pain, enhance physical function, and avoid the pitfalls of traditional analgesics makes it one of the most exciting therapeutic developments in recent years.
As Levicept continues to push forward, the results shared at EULAR 2025 may one day be seen as a defining moment in the journey toward better, safer pain management for chronic joint conditions.
News Credits: Levicept presents new LEVI-04 data at EULAR
Things you may also like: